Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Issue 503BG ControlType 2 DiabetesSpecial Edition - Best of 2010Prediabetes

American Diabetes Association's New Clinical Practice Recommendations Promote A1c as Diagnostic Test for Diabetes and Pre-Diabetes

Faster, easier test could help reduce number of undiagnosed with diabetes and pre-diabetes.

Advertisement

The American Diabetes Association's (ADA) new Clinical Practice Recommendations being published as a supplement to the January issue of Diabetes Care call for the addition of the A1c test as a means of diagnosing diabetes and identifying pre-diabetes. The test has been recommended for years as a measure of how well people are doing to keep their blood glucose levels under control.
 
"We believe that use of the A1c, because it doesn't require fasting, will encourage more people to get tested for Type 2 diabetes and help further reduce the number of people who are undiagnosed but living with this chronic and potentially life-threatening disease.  Additionally, early detection can make an enormous difference in a person's quality of life," said Richard M. Bergenstal, MD, President-Elect, Medicine & Science, ADA.

"Unlike many chronic diseases, Type 2 diabetes actually can be prevented, as long as lifestyle changes are made while blood glucose levels are still in the pre-diabetes range."

A1c is measured in terms of percentages. The test measures a person's average blood glucose levels over a period of up to three months and previously had been used only to determine how well people were maintaining control of their diabetes over time. A person without diabetes would have an A1c of about 5 percent.

Under the new recommendations, which are revised every year to reflect the most current available scientific research, an A1c of 5.7 -- 6.4 percent would indicate that blood glucose levels were in the pre-diabetic range, meaning higher than normal but not yet high enough for a diagnosis of diabetes. That diagnosis would occur once levels rose to an A1c of 6.5 percent or higher.

The ADA recommends that most people with diabetes maintain a goal of keeping A1c levels at or below 7 percent in order to properly manage their disease. Research shows that controlling blood glucose levels helps to prevent serious diabetes-related complications, such as kidney disease, nerve damage and problems with the eyes and gums.

The A1c would join two previous diagnostic tests for diabetes, Fasting Plasma Glucose (FPG) and the Oral Glucose Tolerance Test (OGTT), both of which require overnight fasting. Because the A1c is a simple blood test and does not require fasting, allowing patients this option could increase willingness to get tested, thereby reducing the number of people who have Type 2 diabetes but don't yet know it.

According to the Centers for Disease Control and Prevention, one-fourth of all Americans with diabetes, or 5.7 million people, don't realize they have it. Another 57 million have pre-diabetes and 1.6 million new diagnoses are made every year.

To obtain a copy of the Standards of Medical Care in Diabetes, please contact dkern@diabetes.org.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into one of the nation's leading causes of death by disease.  Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 06 January, 2010 and appeared in  Issue 503BG ControlType 2 DiabetesSpecial Edition - Best of 2010Prediabetes

Past five issues: Issue 756 | Diabetes Clinical Mastery Series Issue 215 | SGLT-2 Inhibitors Special Edition November 2014 | Issue 755 | GLP-1 Special Editions November 2014 |

2014 Most Popular Articles:

Grapefruit Juice May Affect Insulin Resistance
Posted October 23, 2014
New SGLT2 Inhibitor Likely To Be Approved for Type 2 Diabetes
Posted November 14, 2014
FDA Accepts Filing of NDA for Empagliflozin/Metformin Fixed-dose Combination
Posted October 23, 2014
What's Hiding in that Insulin Box?
Posted October 27, 2014
Dietary Magnesium Intake's Role in Decreasing Metabolic Syndrome
Posted October 31, 2014
Handbook of Diabetes, 4th Ed., Excerpt #16: Diabetic Neuropathy
Posted November 02, 2014
New Approach Targets Type 2's Poorly Controlled With Metformin
Posted November 14, 2014
Very Low Carbohydrate, Low Saturated Fat Diet for Type 2 Diabetes Management
Posted November 07, 2014
Interview with NuSirt CEO Joe Cook, Jr: Improving Metformin Treatment, Part 1
Posted November 02, 2014
Exenatide a Noninsulin Addition for Patients Failing Basal Insulin
Posted October 23, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
If the U.S. Affordable Care Act is reversed in the new congress, what impact will that have on your patients?
CME/CE of the Week
Allan Hamdan, MD

Category: Vascular Therapy
Credits: .75


Advertisement


Search Articles On Diabetes In Control